Which has higher earnings and valuation, ELVN or CABA?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A

Is ELVN or CABA more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Cabaletta Bio N/A -131.58% -96.46%

Does the media favor ELVN or CABA?

In the previous week, Enliven Therapeutics had 11 more articles in the media than Cabaletta Bio. MarketBeat recorded 19 mentions for Enliven Therapeutics and 8 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.50 beat Enliven Therapeutics' score of 0.31 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cabaletta Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNM or CABA more profitable?

Immunome's return on equity of -51.15% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Cabaletta Bio N/A -131.58% -96.46%

Does the media favor IMNM or CABA?

In the previous week, Immunome had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 9 mentions for Immunome and 8 mentions for Cabaletta Bio. Immunome's average media sentiment score of 0.68 beat Cabaletta Bio's score of 0.50 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or CABA?

In the previous week, Cabaletta Bio had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 8 mentions for Cabaletta Bio and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Cabaletta Bio's score of 0.50 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, PHVS or CABA?

Pharvaris is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A

Is PHVS or CABA more profitable?

Pharvaris' return on equity of -67.56% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Cabaletta Bio N/A -131.58% -96.46%

Does the media favor PHVS or CABA?

In the previous week, Cabaletta Bio had 2 more articles in the media than Pharvaris. MarketBeat recorded 8 mentions for Cabaletta Bio and 6 mentions for Pharvaris. Cabaletta Bio's average media sentiment score of 0.50 beat Pharvaris' score of 0.34 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cabaletta Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CABA or BHC?

In the previous week, Cabaletta Bio had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 8 mentions for Cabaletta Bio and 3 mentions for Bausch Health Cos. Cabaletta Bio's average media sentiment score of 0.50 beat Bausch Health Cos' score of 0.49 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cabaletta Bio (CABA) Competitors

$3.01 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.02 +0.02 (+0.50%)

As of 06/12/2026 07:56 PM Eastern

Compare

CABA vs. ELVN, IMNM, AUPH, PHVS, and BHC

Should you buy Cabaletta Bio stock or one of its competitors? MarketBeat compares Cabaletta Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cabaletta Bio include Enliven Therapeutics (ELVN), Immunome (IMNM), Aurinia Pharmaceuticals (AUPH), Pharvaris (PHVS), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry.

How does Cabaletta Bio compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Enliven Therapeutics' return on equity of -21.04% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Cabaletta Bio	N/A	-131.58%	-96.46%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Enliven Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, meaning that its stock price is 221% more volatile than the broader market.

In the previous week, Enliven Therapeutics had 11 more articles in the media than Cabaletta Bio. MarketBeat recorded 19 mentions for Enliven Therapeutics and 8 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.50 beat Enliven Therapeutics' score of 0.31 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics presently has a consensus target price of $61.50, suggesting a potential upside of 33.32%. Cabaletta Bio has a consensus target price of $15.50, suggesting a potential upside of 414.95%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Enliven Therapeutics beats Cabaletta Bio on 8 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Immunome?

Immunome (NASDAQ:IMNM) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Immunome has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market.

Immunome currently has a consensus price target of $33.17, indicating a potential upside of 80.45%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 414.95%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Immunome's return on equity of -51.15% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Cabaletta Bio	N/A	-131.58%	-96.46%

44.6% of Immunome shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Immunome had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 9 mentions for Immunome and 8 mentions for Cabaletta Bio. Immunome's average media sentiment score of 0.68 beat Cabaletta Bio's score of 0.50 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cabaletta Bio has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	299.93	-$212.39M	-$2.38	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Summary

Immunome beats Cabaletta Bio on 9 of the 14 factors compared between the two stocks.

How does Cabaletta Bio compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Aurinia Pharmaceuticals has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.19	$287.20M	$2.17	7.29
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Cabaletta Bio's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Cabaletta Bio	N/A	-131.58%	-96.46%

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cabaletta Bio had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 8 mentions for Cabaletta Bio and 3 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Cabaletta Bio's score of 0.50 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, suggesting that its stock price is 221% more volatile than the broader market.

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, indicating a potential upside of 9.04%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 414.95%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Aurinia Pharmaceuticals beats Cabaletta Bio on 10 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Pharvaris' return on equity of -67.56% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Cabaletta Bio	N/A	-131.58%	-96.46%

Pharvaris is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Pharvaris currently has a consensus price target of $49.18, indicating a potential upside of 60.10%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 414.95%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cabaletta Bio had 2 more articles in the media than Pharvaris. MarketBeat recorded 8 mentions for Cabaletta Bio and 6 mentions for Pharvaris. Cabaletta Bio's average media sentiment score of 0.50 beat Pharvaris' score of 0.34 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, meaning that its share price is 221% more volatile than the broader market.

Summary

Cabaletta Bio beats Pharvaris on 7 of the 11 factors compared between the two stocks.

How does Cabaletta Bio compare to Bausch Health Cos?

Cabaletta Bio (NASDAQ:CABA) and Bausch Health Cos (NYSE:BHC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Cabaletta Bio presently has a consensus target price of $15.50, indicating a potential upside of 414.95%. Bausch Health Cos has a consensus target price of $8.00, indicating a potential upside of 58.26%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

78.7% of Bausch Health Cos shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cabaletta Bio has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Cabaletta Bio has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Cabaletta Bio's return on equity of -131.58% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Bausch Health Cos has higher revenue and earnings than Cabaletta Bio. Bausch Health Cos is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Bausch Health Cos	$10.27B	0.18	$157M	-$3.24	N/A

In the previous week, Cabaletta Bio had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 8 mentions for Cabaletta Bio and 3 mentions for Bausch Health Cos. Cabaletta Bio's average media sentiment score of 0.50 beat Bausch Health Cos' score of 0.49 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cabaletta Bio beats Bausch Health Cos on 10 of the 15 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$490.78M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.54	20.00	24.00	24.42
Price / Sales	N/A	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.59	8.32	10.55	6.82
Net Income	-$167.86M	$23.94M	$3.57B	$337.56M
7 Day Performance	-5.94%	1.84%	0.59%	1.16%
1 Month Performance	-9.06%	-0.04%	1.55%	3.16%
1 Year Performance	51.26%	44.82%	25.41%	30.60%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.9134 of 5 stars	$3.01 flat	$15.50 +415.0%	+51.3%	$490.78M	N/A	N/A	50	Analyst Downgrade
ELVN Enliven Therapeutics	2.8158 of 5 stars	$33.63 -3.1%	$61.80 +83.8%	+110.5%	$2.11B	N/A	N/A	50	Gap Down
IMNM Immunome	3.6804 of 5 stars	$18.61 +0.2%	$33.17 +78.2%	+99.8%	$2.10B	$6.94M	N/A	40	Analyst Forecast Gap Down
AUPH Aurinia Pharmaceuticals	2.5568 of 5 stars	$15.66 -1.1%	$17.25 +10.2%	+93.4%	$2.04B	$283.05M	7.22	300
PHVS Pharvaris	3.334 of 5 stars	$31.59 +1.6%	$49.18 +55.7%	+84.0%	$2.03B	N/A	N/A	30	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. ELVN, IMNM, AUPH, PHVS, and BHC

How does Cabaletta Bio compare to Enliven Therapeutics?

Summary

How does Cabaletta Bio compare to Immunome?

Summary

How does Cabaletta Bio compare to Aurinia Pharmaceuticals?

Summary

How does Cabaletta Bio compare to Pharvaris?

Summary

How does Cabaletta Bio compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. ELVN, IMNM, AUPH, PHVS, and BHC

How does Cabaletta Bio compare to Enliven Therapeutics?

Is ELVN or CABA more profitable?

Which has higher earnings and valuation, ELVN or CABA?

Which has more risk & volatility, ELVN or CABA?

Does the media favor ELVN or CABA?

Do analysts recommend ELVN or CABA?

Do institutionals and insiders hold more shares of ELVN or CABA?

Summary

How does Cabaletta Bio compare to Immunome?

Which has more volatility & risk, IMNM or CABA?

Do analysts rate IMNM or CABA?

Is IMNM or CABA more profitable?

Do insiders & institutionals believe in IMNM or CABA?

Does the media favor IMNM or CABA?

Which has higher earnings and valuation, IMNM or CABA?

Summary

How does Cabaletta Bio compare to Aurinia Pharmaceuticals?

Which has better valuation & earnings, AUPH or CABA?

Is AUPH or CABA more profitable?

Do institutionals & insiders believe in AUPH or CABA?

Does the media favor AUPH or CABA?

Which has more risk & volatility, AUPH or CABA?

Do analysts recommend AUPH or CABA?

Summary

How does Cabaletta Bio compare to Pharvaris?

Is PHVS or CABA more profitable?

Which has stronger valuation & earnings, PHVS or CABA?

Do analysts recommend PHVS or CABA?

Does the media favor PHVS or CABA?

Which has more volatility and risk, PHVS or CABA?

Summary

How does Cabaletta Bio compare to Bausch Health Cos?

Do analysts rate CABA or BHC?

Do institutionals & insiders hold more shares of CABA or BHC?

Which has more volatility & risk, CABA or BHC?

Is CABA or BHC more profitable?

Which has stronger earnings & valuation, CABA or BHC?

Does the media prefer CABA or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools